Approach to TB screening prior to commencing biologics. Hyrich K #EULAR2024 @RheumNow https://t.co/j3PI0PHpqW

• https://twitter.com/synovialjoints/status/1801596567758967036/photo/1

New imaging technique PET/CT imaging with 68Gallium-labelled Fibroblast Activation Protein Inhibitor-04 (68Ga-FAPI-04) enables the visualization of fibroblast activation in vivo. No correlations with MSUS findings were found. Fibroblast activation detected by 68Ga-FAPI-04-PET/CT… https://t.co/4VTF1YDzYd https://t.co/Y8Hmlf3sWl

• https://twitter.com/i/web/status/1801594559400395260
• https://twitter.com/synovialjoints/status/1801594559400395260/photo/1

Cycle or swap 2? Post failure to a first TNFi in patients with PsA, there was no difference in cycle versus swap to IL17i for drug retention rate or disease activity. In male PsA patients a cycle strategy had a longer drug retention rate compared to a swap (IL-17i) strategy.… https://t.co/5BykvDwFWV https://t.co/GfcnIltV2A

• https://twitter.com/i/web/status/1801590870908518546
• https://twitter.com/synovialjoints/status/1801590870908518546/photo/1

Prof Hellmich takes us through “What is new?” In ANCA #vasculitis A tour de force in management strategies and, continuing a theme of #EULAR2024, ends with a study suggesting the potential of #CAR-T! @RheumNow https://t.co/K3dDqZhUvD

• https://twitter.com/DrMiniDey/status/1801589388272390545/photo/1

What is better for #Rx of #osteoporosis? #Denosumab or ##Zoledronic acid? #Prolia compared to #Aclasta Giant admin US data of 125,000 Rx niaive women with #OP ▶️Prolia has LESS fractures! POS0583 #EULAR2024 @eular_org @RheumNow https://t.co/eo1ny2VIRf

• https://twitter.com/Janetbirdope/status/1801588758711541852/photo/1
• https://twitter.com/Janetbirdope/status/1801588758711541852/photo/1

✨ Delighted to be chairing the session on newly diagnosed #RMDs in the PARE programme this afternoon, featuring a fantastic panel of speakers! 👥 Perfect for patients and clinicians alike! 👇🏼 All details below- hope to see you there @RheumNow #EULAR2024 https://t.co/8RmcH8qprJ

• https://twitter.com/DrMiniDey/status/1801588323594498324/photo/1
• https://twitter.com/DrMiniDey/status/1801588323594498324/photo/1

What is better in #PsA #psoriatic #arthritis #TNFi or #apremilast #PDE4i #COREVITAS database study in #PsA YOU can guess the answer! 1st line advanced RxTNFi lasts longer - retention Vs PDE4i #EULAR2024 @RheumNow @eular_org POS0990 https://t.co/VmYG6Rj87c

• https://twitter.com/Janetbirdope/status/1801585969130356929/photo/1

Cycle or Swap? The swap strategy (SG) (i.e. from TNFi to IL17i) had higher retention rates compared to the change strategy (CG) choice in PsA patients who failed the first line of advanced treatment. The 5 years retention rate in SG was higher than in CG (57,8% vs 45,2%; p=0.1).… https://t.co/pH5rFI00vK https://t.co/XqTHO1tIr3

• https://twitter.com/i/web/status/1801585922292519240
• https://twitter.com/synovialjoints/status/1801585922292519240/photo/1
• https://twitter.com/synovialjoints/status/1801585922292519240/photo/1

Discovery in joint and skin disease - PsA Three different clusters #EULAR2024 @RheumNow https://t.co/Nj5HZOVqas

• https://twitter.com/bella_mehta/status/1801584877097336910/photo/1

Predicting who will develop ▶️#GCA In #Swedish study with #PMR ⬆️ in HIGH ESR/CRP ⬆️female ⬇️ if hip pain/stiffness Not all sig 1 mo after #prednisone started Only 9% with #polymyalgia #rheumatica developed #GCA ? ⬇️GCA % in PMR over time #POS0411 @eular_org @RheumNow https://t.co/UMhxlYd0Pv

• https://twitter.com/Janetbirdope/status/1801542496675143886/photo/1

EULAR 2024 Highlights: Friday’s Recap with RheumNow https://t.co/r46kiGalBh

• Dr. John Cush

RheumNow’s expanded coverage of the #EULAR2024 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our faculty.